Jul. 30 at 12:39 PM
$ELTP $GME $WEN $JNJ $BTC.X
Elite Pharmaceuticals, a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2026
Consolidated revenues for Fiscal 2026 were
$148.9 million, an increase of
$64.8 million or approximately 77% as compared to the comparable period of the prior fiscal year. Income from operations was
$49.1 million, an increase of
$29.5 million or approximately 151% from the comparable period of the prior year. The increase in income from operations was primarily attributed to Elite’s Lisdexamfetamine, initially launched at the end of the prior fiscal year, having a full year contribution, revenues from Oxycodone Acetaminophen tablets launched during Fiscal 2026, combined with Naltrexone tablets and Phentermine tablets being launched exclusively under the Elite label during Fiscal 2026 and strong overall growth throughout the Elite label product lines.
